S'abonner

Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study - 19/04/17

Doi : 10.1016/j.jaci.2016.08.027 
Vincent Barlogis, MD a, b, c, , Nizar Mahlaoui, MD b, d, e, Pascal Auquier, MD, PhD c, Isabelle Pellier, MD, PhD b, f, Fanny Fouyssac, MD b, g, Camille Vercasson, MS c, Maya Allouche, SC a, Carolina Brito De Azevedo, SC b, Felipe Suarez, MD, PhD b, e, h, i, Despina Moshous, MD, PhD b, d, e, Bénédicte Neven, MD, PhD b, d, e, Marlène Pasquet, MD, PhD b, j, Eric Jeziorski, MD, PhD b, k, Nathalie Aladjidi, MD b, l, Nicolas Schleinitz, MD, PhD b, m, Caroline Thomas, MD b, n, Virginie Gandemer, MD, PhD b, o, Françoise Mazingue, MD b, p, Patrick Lutz, MD b, q, Olivier Hermine, MD, PhD b, e, h, Capucine Picard, MD, PhD b, d, e, Stéphane Blanche, MD, PhD b, d, e, Gérard Michel, MD a, b, c, Alain Fischer, MD, PhD b, d, e, r
a Department of Pediatric Hematology-Oncology, Assistance Publique-Hôpitaux de Marseille, Marseille, France 
b French National Reference Center for Primary Immune Deficiency (CEREDIH), Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France 
c Department of Public Health–EA 3279 Research Unit, University Hospital Marseille, Aix-Marseille University, Marseille, France 
d Pediatric Immuno-Haematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France 
e INSERM UMR1163, Imagine Institute, Necker Medical School, Sorbonne Paris Cité, University Paris Descartes, Paris, France 
f Department of Pediatric Oncohematology, University Hospital of Angers, Angers, France 
g Department of Pediatric Hematology-Oncology, University Hospital of Nancy, Nancy, France 
h Adult Hematology Unit, Necker University Hospital, APHP, University Paris Descartes, Paris, France 
i CNRS ERL8254, Imagine Institute, Necker Medical School, Sorbonne Paris Cité, University Paris Descartes, Paris, France 
j Département d'Hématologie, Centre Hospitalier Universitaire Toulouse Purpan and INSERM, CRCT, IUCT-Oncopole, Toulouse, France 
k Service de Pédiatrie Générale et Infectiologie et Immunologie Clinique, Hôpital Arnaud de Villeneuve, Montpellier University Hospital, Montpellier, France 
l Department of Pediatric Hematology and CIC 0005, INSERM CICP, University Hospital of Bordeaux, Bordeaux, France 
m Department of Internal Medicine, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France 
n Pediatric Hematology-Oncology Unit, Hôpital Mère Enfant, University Hospital of Nantes, Nantes, France 
o Department of Pediatric Hematology/Oncology, University Hospital of Rennes, Rennes, France 
p Department of Pediatrics, Hôpital Jeanne de Flandre, University Hospital of Lille, Lille, France 
q Pediatric Hematology-Oncology, EA3430, Strasbourg, France 
r Collège de France, Paris, France 

Corresponding author: Vincent Barlogis, MD, Department of Pediatric Hematology Oncology, Hôpital d'enfants La Timone and Université Aix-Marseille, Marseille, France.Department of Pediatric Hematology OncologyHôpital d'enfants La Timone and Université Aix-MarseilleMarseilleFrance

Abstract

Background

Most children with primary immunodeficiencies (PIDs) now reach adulthood. However, few studies have evaluated their health status and health-related quality of life (HRQoL).

Objective

To investigate long-term morbidity, the French Reference Center for PIDs initiated a prospective multicenter cohort: the French Childhood Immune Deficiency Long-term Cohort. The data collected were used to assess the physical health condition of patients who reached adulthood and the effect on their quality of life.

Methods

Patients were asked to complete health status questionnaires. A severity score (grade 1 [mild] to grade 4 [life-threatening]) was assigned to each health condition. The HRQoL of patients was compared with age- and sex-matched French normal values by using the 36-item Short-Form Survey (SF-36) HRQoL questionnaire.

Results

Among 329 participants, the mean age at evaluation was 27.6 years, with a 21-year mean follow-up after diagnosis; 43% reported at least 1 grade 4 health condition, and 86% reported at least 1 grade 3 (severe) or 4 health condition. Twenty-five (7.6%) patients had been treated for cancer. Compared with the French normal values, adults with PIDs scored significantly lower for all HRQoL domains. HRQoL was strongly associated with the burden of health conditions. The association with grade 4 or grade 3-4 health conditions was highly significant for all physical and mental domains.

Conclusion

Adults with PIDs diagnosed during childhood experienced a heavy burden of health conditions, which affected their HRQoL. Our results emphasize the need to closely monitor this vulnerable population.

Le texte complet de cet article est disponible en PDF.

Key words : Primary immunodeficiency, childhood, young adults, health status, quality of life

Abbreviations used : CEREDIH, CTCAE, CVID, ENT, F-CILC, F-CILSG, HRQoL, HSCT, PID, SF-36


Plan


 Supported by the French National Program for Clinical Research (PHRC; EudraCT trial no. 2012-A0033-35, Ministry of Health).
 Disclosure of potential conflict of interest: N. Schleinitz has received board membership from Baxalta, LFB, and CSL Behring and payment for lectures from LFB and CSL Behring. O. Hermine has received board membership and consultancy fees from AB Science; he or his institution has received grants pending from AB science, Novartis, and Celgene; and he has stock options with AB science. G. Michel has received a grant from the French National Program for Clinical Research for this work under consideration for publication. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 139 - N° 4

P. 1275 - avril 2017 Retour au numéro
Article précédent Article précédent
  • Mast cells are associated with the onset and progression of celiac disease
  • Barbara Frossi, Claudio Tripodo, Carla Guarnotta, Antonio Carroccio, Marco De Carli, Stefano De Carli, Marco Marino, Antonino Calabrò, Carlo E. Pucillo
| Article suivant Article suivant
  • Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation
  • M. Teresa de la Morena, David Leonard, Troy R. Torgerson, Otavio Cabral-Marques, Mary Slatter, Asghar Aghamohammadi, Sharat Chandra, Luis Murguia-Favela, Francisco A. Bonilla, Maria Kanariou, Rongras Damrongwatanasuk, Caroline Y. Kuo, Christopher C. Dvorak, Isabelle Meyts, Karin Chen, Lisa Kobrynski, Neena Kapoor, Darko Richter, Daniela DiGiovanni, Fatima Dhalla, Evangelia Farmaki, Carsten Speckmann, Teresa Español, Anna Shcherbina, Imelda Celine Hanson, Jiri Litzman, John M. Routes, Melanie Wong, Ramsay Fuleihan, Suranjith L. Seneviratne, Trudy N. Small, Ales Janda, Liliana Bezrodnik, Reinhard Seger, Andrea Gomez Raccio, J. David M. Edgar, Janet Chou, Jordan K. Abbott, Joris van Montfrans, Luis Ignacio González-Granado, Nancy Bunin, Necil Kutukculer, Paul Gray, Gisela Seminario, Srdjan Pasic, Victor Aquino, Christian Wysocki, Hassan Abolhassani, Morna Dorsey, Charlotte Cunningham-Rundles, Alan P. Knutsen, John Sleasman, Beatriz Tavares Costa Carvalho, Antonio Condino-Neto, Eyal Grunebaum, Helen Chapel, Hans D. Ochs, Alexandra Filipovich, Mort Cowan, Andrew Gennery, Andrew Cant, Luigi D. Notarangelo, Chaim M. Roifman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.